By contrast, the second category includes the degeneration of downstream neurons or damage-related biomarkers, mainly the cerebrospinal fluid tau protein, such as tau protein and phosphorylation of tau, which are conducive to diagnose the early AD patients without clinical symptoms (46). This evidence concerns the gene MAPT and Alzheimer disease.